MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...
Hosted on MSN
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth
Michael H. Carrel, CEO, highlighted "a very strong third quarter with total revenue of $134 million, reflecting a 16% increase year-over-year." He cited expanding adoption across key franchises and ...
AtriCure (NASDAQ:ATRC) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results